Ciprofloxacin: Nursing Drug Guide, Tendon Rupture & NCLEX Review
Healthcare medication guide: before every dose, screen for tendon injury risk (especially age over 60 and concurrent prednisone or other corticosteroids), aminophylline or methylxanthine co-therapy, myasthenia gravis history, and separation from magnesium or aluminum antacids—fluoroquinolones can cause irreversible tendon rupture and serious CNS toxicity.
Ciprofloxacin and other fluoroquinolones are associated with tendinitis and tendon rupture in all ages, most often the Achilles tendon. Risk is highest in patients over 60, those taking corticosteroids, and patients with kidney, heart, or lung transplants. Rupture can occur during therapy or months after completion. Labeling also warns of CNS toxicity (confusion, tremor, seizures), peripheral neuropathy, and fatal reactions with theophylline. Before every dose, complete medication reconciliation, assess gait and joint complaints, verify antacid separation, and hold plus escalate at the first sign of tendon pain, neuro symptoms, or serious hypersensitivity.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before the first and each subsequent dose, screen quinolone allergy, tendon and joint symptoms, corticosteroid and transplant risk factors, theophylline or tizanidine on the MAR, renal function, and antacid or multivalent cation timing. Hold ciprofloxacin and notify the prescriber or pharmacist for new heel or shoulder pain, confusion or tremor, burning numbness in hands or feet, serious rash, or watery diarrhea with fever.
Most common brand names
Ciprofloxacin is available as generic tablets and, in some markets, as Cipro and other brand formulations. This guide reflects FDA ciprofloxacin tablet prescribing information (250 mg and 500 mg strengths). Verify route, strength, and whether the order is oral or IV before administration—formulations are not interchangeable without a new prescriber order.
Ciprofloxacin is a fluoroquinolone, not a penicillin, cephalosporin, or macrolide. Do not assume cross-coverage with other antibiotic classes; allergy documentation must specify quinolone hypersensitivity when present.
Why we give it — Indications
Ciprofloxacin treats infections caused by susceptible organisms when benefit outweighs fluoroquinolone risks. Nurses commonly see it for urinary tract infection, complicated UTI/pyelonephritis, respiratory infections including pneumonia, skin and soft-tissue infection, bone and joint infection, infectious diarrhea, and gonococcal urethritis/cervicitis per labeled regimens.
| Use (adults, oral examples) | Typical labeled dose | Duration (usual) |
|---|---|---|
| Uncomplicated UTI | 250 mg every 12 hours | 3 days |
| Complicated UTI / pyelonephritis | 500 mg every 12 hours | 7–14 days |
| Lower respiratory (mild/moderate) | 500 mg every 12 hours | 7–14 days |
| Skin / soft tissue (mild/moderate) | 500 mg every 12 hours | 7–14 days |
| Uncomplicated gonorrhea | 250 mg single dose | Single dose |
On a small screen, swipe or scroll sideways to see the full table.
FDA drug safety communications advise restricting oral fluoroquinolones for uncomplicated infections when other options are available, because disabling and potentially permanent serious adverse reactions can occur. Institutional antimicrobial stewardship and indication-specific protocols should guide selection—nurses escalate concerns when fluoroquinolones are ordered without a clear susceptibility or safety rationale.
How it works
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication in susceptible bacteria. Nursing focus extends beyond coverage: ciprofloxacin is a CYP1A2 inhibitor, raising levels of drugs such as theophylline and is contraindicated with tizanidine per labeling. It also carries class warnings for tendon injury, CNS toxicity, and peripheral neuropathy—these risks drive hold rules and patient teaching more than the mechanism alone.
Dosing overview
Verify indication, renal function, and route against current prescribing information. Doses below are from FDA ciprofloxacin tablet labeling (250 mg and 500 mg strengths); some indications in the full label use 750 mg every 12 hours—confirm the MAR against the complete guideline for your patient’s infection.
Renal dose adjustment (creatinine clearance)
| Creatinine clearance (mL/min) | Dose |
|---|---|
| > 50 | Usual dosage per indication |
| 30–50 | 250–500 mg every 12 hours |
| 5–29 | 250–500 mg every 18 hours |
| Hemodialysis or peritoneal dialysis | 250–500 mg every 24 hours (after dialysis) |
On a small screen, swipe or scroll sideways to see the full table.
Pediatrics: Labeling limits routine pediatric use to specific indications (e.g., inhalational anthrax post-exposure, complicated UTI in older children); pediatric patients have increased musculoskeletal adverse events—use pharmacy and the full label for weight-based regimens.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy for guidance.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Tmax (oral) | 1–2 hours after dose (delayed with food) | Peak slightly later with meals; overall absorption not substantially reduced with food |
| Half-life | ~4 hours (normal renal function) | Prolonged when renal function is reduced—adjust interval per CrCl |
| Antacids / multivalent cations | May reduce bioavailability up to ~90% | Give ciprofloxacin at least 2 hours before or 6 hours after magnesium/aluminum antacids, sucralfate, or calcium/iron/zinc products |
| Elimination | ~40–50% excreted unchanged in urine | Monitor renal function; urine drug levels exceed serum early after dose |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Allergy history: ciprofloxacin, any fluoroquinolone, or product component
- MAR review for tizanidine (contraindicated), theophylline/aminophylline, warfarin, methotrexate, corticosteroids
- Recent basic metabolic panel / renal function for dose interval; gait and joint assessment (tendon risk)
- History of myasthenia gravis, seizures, or CNS disease—use with caution per labeling
- Scheduled antacids, PPI with sucralfate, or iron—plan 2-hour before / 6-hour after separation
Contraindications
- Hypersensitivity to ciprofloxacin, any quinolone, or formulation component
- Concomitant tizanidine (labeled contraindication—marked increase in tizanidine exposure)
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Theophylline / aminophylline | Decreased clearance; serious/fatal reactions reported (seizure, cardiac arrest) | Monitor theophylline level; hold and notify if toxicity signs; do not start without interaction review |
| Warfarin | May enhance anticoagulant effect | Monitor prothrombin time/INR closely during concurrent therapy |
| Tizanidine | Contraindicated—large increase in exposure and hypotension/sedation | Hold ciprofloxacin until MAR reconciled; never administer together |
| Magnesium/aluminum antacids, iron, calcium, zinc | Greatly reduced absorption | Separate dosing by at least 2 h before or 6 h after ciprofloxacin |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral tablets: May be taken with or without food; food delays peak but does not substantially reduce overall absorption per labeling. Use medication administration rights and swallow with water. Complete the prescribed course unless hold criteria are met—early stopping contributes to resistance per labeling.
- Administer at least 2 hours before or 6 hours after antacids containing magnesium or aluminum, sucralfate, or products with calcium, iron, or zinc
- Independent double-check of high-risk combinations (theophylline, warfarin) on the MAR
- Document administration, fluid intake, and any joint or neuro complaints
- IV ciprofloxacin: not detailed in the reviewed oral tablet label—follow institutional IV antibiotic and infusion protocols when ordered
Expected therapeutic response
- Decreasing fever and improving dysuria, urgency, or flank pain when treating susceptible UTI
- Improving respiratory symptoms and white blood cell trend when treating susceptible respiratory infection
- Stable mental status without new confusion, tremor, or insomnia
- No new tendon pain or gait change during or after therapy
Red flags — Stop and act
Hold ciprofloxacin and escalate immediately when serious toxicity is suspected.
- Sudden pain, swelling, or inability to use a joint—possible tendon rupture; rest joint and notify prescriber urgently
- Confusion, hallucinations, tremor, seizure, or suicidal thoughts—CNS toxicity per labeling
- Burning, tingling, or numbness in hands or feet—possible peripheral neuropathy; stop drug to prevent irreversible injury
- Signs of hepatitis: jaundice, dark urine, severe abdominal pain
- Angioedema, bronchospasm, or systemic allergic reaction (some after first dose)
- Serious rash or mucosal involvement
- Watery diarrhea, abdominal pain, fever—evaluate for C. difficile colitis
- Worsening weakness or respiratory distress in myasthenia gravis
- Theophylline toxicity signs when co-prescribed (tachycardia, vomiting, seizure)
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Nausea, diarrhea, vomiting, abdominal pain | Most frequent drug-related events in trials | Supportive care; differentiate mild GI upset from CDAD or hepatitis |
| Tendinitis / tendon rupture | Boxed warning; higher risk age >60, steroids, transplant | Stop drug, rest affected limb, urgent prescriber/surgical review |
| CNS effects | Dizziness, insomnia, confusion; convulsions reported | Stop drug, neurologic assessment, fall precautions |
| Peripheral neuropathy | Rare but may be irreversible if continued | Stop at first sensory symptoms; document and notify prescriber |
| Hepatotoxicity / serious hypersensitivity | Includes fatal cases postmarketing | Stop drug; order liver function tests per prescriber; treat severe reaction per protocol |
| CDAD | Reported with nearly all antibacterials | Isolation precautions per facility; stool studies per order |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Labeling reports reversible renal toxicity in some acute overdose cases. Management includes emptying the stomach by induced vomiting or gastric lavage, careful observation, supportive treatment, and monitoring renal function.
Management
Maintain adequate hydration. Magnesium, aluminum, or calcium-containing antacids may reduce absorption of ciprofloxacin in overdose context per labeling. Only a small amount (<10%) is removed by hemodialysis or peritoneal dialysis. No specific antidote is listed in the reviewed prescribing information. Contact local poison control or toxicology services per facility protocol and local emergency guidance for severe overdose.
Look-alike / sound-alike and error prevention
- Ciprofloxacin vs cephalexin—both start with “c” but different classes; verify allergy class on MAR
- Cipro vs Ciprofloxacin HCl—confirm strength (250 mg vs 500 mg) and indication-specific dose
- Every-12-hour vs every-24-hour—renal adjustment errors are common; pharmacy should verify CrCl
- IV-to-oral switch—use labeled equivalent dosing when converting per prescriber and pharmacy
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Tendon screen | Ask about exercise, steroids, and new heel or shoulder pain at every shift |
| Antacid timing | Chart separation from PPI/antacid/iron—many missed doses are “given” but not absorbed |
| Theophylline patients | Flag any tachycardia, nausea, or tremor as possible combined toxicity |
| GI teaching | Report watery diarrhea—not only “antibiotic stomach upset” |
| Commonly missed | Continuing cipro after tendon pain; giving with breakfast calcium supplement |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults (>60) | Highest tendon rupture risk; also greater QT-interval sensitivity with QT-prolonging co-drugs |
| Corticosteroid therapy | Further increased tendon rupture risk—coordinate with prescriber before starting |
| Organ transplant recipients | Labeling identifies kidney, heart, or lung transplant as higher tendon risk |
| Renal impairment | Reduce dosing interval per CrCl; monitor renal function during prolonged therapy |
| Myasthenia gravis | Postmarketing exacerbation reported—avoid unless benefit clearly outweighs risk |
| Pregnancy | Category C; safety not established—use only if benefit justifies risk to fetus and mother |
| Lactation | Excreted in human milk; infant exposure unknown—decision to discontinue nursing or drug per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Joint and tendon symptoms, gait, and ability to bear weight
- Mental status, sleep, tremor, or new neurologic complaints
- Renal function and creatinine clearance trend for dose appropriateness
- Theophylline level and toxicity signs when methylxanthines are concurrent
- INR or prothrombin time when warfarin is concurrent
- GI tolerance, hydration, and stool character
- Infection response: temperature, WBC, urine symptoms, or respiratory status per plan
Document
- Tendon and interaction screening before first dose
- Antacid or multivalent cation separation education and administration times
- Any held doses with prescriber/pharmacist notification and patient symptoms
- Patient teaching on tendon pain, neuro symptoms, and severe diarrhea
Patient teaching
- Take exactly as directed; do not skip antacid separation rules—ask pharmacy how to schedule iron, calcium, or stomach medicines
- Stop exercising at the first sign of tendon pain, swelling, or inability to move a joint, and contact the prescriber immediately
- Report confusion, tremor, depression, insomnia, numbness, tingling, or burning in hands or feet promptly
- Report watery diarrhea, blood in stool, or severe abdominal pain—even after stopping the antibiotic
- Avoid excessive sunlight or UV exposure—photosensitivity reactions reported with quinolones
- Do not share antibiotics; complete the course only if the prescriber continues the drug after safety review
- Breastfeeding: discuss risks and benefits with the prescriber—drug is present in breast milk per labeling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to ciprofloxacin or any fluoroquinolone
- Concomitant tizanidine on the MAR
- New or worsening tendon pain, swelling, inflammation, or joint weakness
- Confusion, hallucinations, tremor, seizure, or other significant CNS toxicity
- Peripheral neuropathy symptoms (pain, burning, tingling, numbness, weakness)
- Serious allergic reaction, severe rash, or signs of hepatitis
- Watery diarrhea with fever or suspected C. difficile pending evaluation
- Acute worsening of myasthenia gravis symptoms
- Elevated theophylline level or toxicity signs when theophylline is co-prescribed
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Ciprofloxacin is still ordered for susceptible infections—but fluoroquinolone safety warnings mean nurses must pair administration with tendon and neuro surveillance, not only infection response.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and renal-adjusted interval verified
- Quinolone allergy and tizanidine contraindication reviewed on MAR
- Theophylline, warfarin, methotrexate, and corticosteroid entries flagged
- Antacid, iron, calcium, or zinc products scheduled outside the 2-hour before / 6-hour after window
2. Safety badge
Fluoroquinolone — tendon, CNS, and interaction screening requiredTreat tendon and theophylline risk with the same rigor as institutional high-alert workflows even when the product is not on a formal high-alert list in every facility.
3. Hold and question rules
- Any new heel or shoulder pain → hold next dose and notify prescriber same shift
- Tizanidine on MAR → hold ciprofloxacin until pharmacy reconciliation completes
- Patient on prednisone with new gait change → urgent prescriber review before further doses
4. Critical teach-back questions
- “What joint symptoms should you report immediately?” (Patient should name pain, swelling, or inability to use a joint and stopping exercise.)
- “How should you take antacids or iron with this antibiotic?” (Patient should describe separating doses per teaching—typically hours apart.)
5. Care coordination
Pharmacist: Renal dose adjustment, theophylline level monitoring, tizanidine contraindication, antacid timing
Prescriber: Alternative antibiotic when fluoroquinolone risk outweighs benefit; tendon or neuropathy management
🧠 Quick mental checklist
- Is the patient over 60, on steroids, or post-transplant?
- Are theophylline, tizanidine, or warfarin on the MAR?
- What is creatinine clearance—and is the dose interval correct?
- Were antacids, iron, or calcium separated by at least 2 hours before or 6 hours after?
- Any new tendon pain, confusion, tremor, numbness, or watery diarrhea?
Ciprofloxacin NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for ciprofloxacin tendon and interaction safety using a tabbed inpatient case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), theophylline trend interpretation, documentation cloze, ordered response, and matrix urgency—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Ciprofloxacin 500 mg PO every 12 hours (day 3 of complicated UTI regimen)
- Prednisone 20 mg PO daily — given 0800
- Aminophylline 400 mg PO twice daily — due 0800 and 2000
- Calcium carbonate 500 mg PO with breakfast — given 0730
- Creatinine 1.4 mg/dL (baseline 1.0); estimated CrCl ~42 mL/min per pharmacy sticker
- Theophylline level 22 mcg/mL (therapeutic range often 10–20 mcg/mL per facility)
- WBC trending down; urine culture sensitivities show organism susceptible to ciprofloxacin
- 71-year-old with COPD exacerbation history; long-term oral steroid for COPD
- Completed marathon training until illness; now deconditioned
- No documented quinolone allergy
- Home medications include methylxanthine and intermittent calcium for reflux
- Patient reports sharp pain behind right heel when walking to bathroom; visible swelling noted
- Mild hand tremor; states “I feel shaky” since yesterday’s second cipro dose
- Calcium carbonate taken with breakfast 45 minutes before scheduled ciprofloxacin
- Pharmacy note: “Renal dose and theophylline interaction review due”
Answer key & rationale
Frequently asked questions
Why is tendon rupture the main nursing safety concern with ciprofloxacin?
Prescribing information warns that fluoroquinolones including ciprofloxacin are associated with tendinitis and tendon rupture in all ages, most often the Achilles tendon. Risk increases in patients over 60, those taking corticosteroids, and patients with kidney, heart, or lung transplants. Rupture can occur during or after therapy, including months later.
When should a nurse hold ciprofloxacin?
Hold for hypersensitivity to ciprofloxacin or any quinolone; concomitant tizanidine; new tendon pain, swelling, or inability to use a joint; CNS toxicity such as confusion, tremor, or seizures; peripheral neuropathy symptoms; serious rash or hepatitis; watery diarrhea with fever suggesting C. difficile; worsening myasthenia gravis; or elevated theophylline level when ciprofloxacin and theophylline are co-prescribed until pharmacist or prescriber review.
Does ciprofloxacin interact with theophylline?
Labeling reports serious and fatal reactions when ciprofloxacin and theophylline are given together, including cardiac arrest, seizure, status epilepticus, and respiratory failure. Ciprofloxacin decreases theophylline clearance and raises serum theophylline levels. If concomitant use cannot be avoided, monitor theophylline levels and adjust dosing.
What adverse effects matter most for nurses?
Priority nursing concerns include tendinitis and tendon rupture, CNS effects and seizures, peripheral neuropathy, serious hypersensitivity and hepatotoxicity, C. difficile-associated diarrhea, myasthenia gravis exacerbation, and common GI effects (nausea, diarrhea) that may mask serious toxicity.
Is ciprofloxacin safe in pregnancy and breastfeeding?
Labeling states safety and effectiveness in pregnant and lactating women have not been established. Pregnancy category C: use during pregnancy only if potential benefit justifies risk. Ciprofloxacin is excreted in human milk; amount absorbed by the nursing infant is unknown. A decision should be made to discontinue nursing or discontinue the drug, weighing importance of the drug to the mother.
References
- U.S. National Library of Medicine. Ciprofloxacin tablet — Full prescribing information. DailyMed (setid fbcd32c0-bcfd-4cc7-8e81-6612bc0cfc45).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbcd32c0-bcfd-4cc7-8e81-6612bc0cfc45
- U.S. Food and Drug Administration. FDA advises restricting use of oral fluoroquinolone antibiotics for certain uncomplicated infections. Drug Safety Communication.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-use-oral-fluoroquinolone-antibiotics-certain
- Drugs and Lactation Database (LactMed). Ciprofloxacin. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK540969/
- U.S. National Library of Medicine. Ciprofloxacin — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a688010.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.